Actively Recruiting
Phase 12 Study Evaluating mRNA-4359 Alone and Combined with Pembrolizumab, Ipilimumab, and Nivolumab in Adults and Adolescents with Advanced Solid Tumors
Led by ModernaTX, Inc. · Updated on 2026-07-14
361
Participants Needed
39
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of an investigational drug called mRNA-4359 alone and combined with other immune checkpoint blockerspembrolizumab, ipilimumab, and nivolumabin adults and adolescents with advanced solid tumors. The study includes participants with various cancers such as melanoma, non-small-cell lung cancer NSCLC, bladder cancer, colorectal cancer, and breast cancer who often have not responded to standard treatments. This Phase 12 trial aims to determine safe dosing levels and monitor side effects of these combinations. Participants will receive mRNA-4359 via intramuscular injection either alone or in combination with pembrolizumab, ipilimumab, and nivolumab, which are given by intravenous infusion. Different groups include those receiving mRNA-4359 alone or with pembrolizumab for checkpoint inhibitor refractory melanoma or NSCLC, as well as treatment-naive melanoma or NSCLC patients receiving mRNA-4359 combined with pembrolizumab or with ipilimumab and nivolumab. Dose escalation and expansion phases are included to find recommended dosing and to assess safety and response. During the study, participants will be closely monitored for dose-limiting toxicities, adverse events, and treatment response using imaging and tumor assessments up to 27 or 60 months depending on the group. Tumor biopsies will be collected before and during treatment when possible to study immune responses. Quality of life assessments and long-term survival will also be tracked. The study involves regular visits for treatment administration, monitoring, and evaluations over several months to years.
CONDITIONS
Brief Title
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Research Team
M
Moderna WeCare Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here